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INTRODUCTION
Worldwide, breast cancer is the most common cancer in 
women and its incidence has been increasing every year, reach-
ing up to 22.9% of all female malignancies [1,2]. Likewise, breast 
cancer in Korea remains the second most common cancer fol-
lowing thyroid cancer [3]. The peak age of breast cancer is in 
the 60s in Western countries and women under 35 years old 
at the time of diagnosis accounts for less than 4% of all breast 
cancer patients [4]. However, in Korea, the peak age is in the 
40s and the proportion of patients of this age is much higher 
than it is in the West [4,5]. Although it has been reported that 
younger patients generally have poorer prognoses than older 
patients, there are still debates on what the optimal cut-off age 
for defining a young age is, or whether the age itself serves as a 
prognostic factor. A recent study using the large nationwide 
Korean Breast Cancer Society (KBCS) registry suggests that 
an age of 35 years at the time of diagnosis is a reasonable cut-
off point for the determination of a young age for breast cancer 
[6,7]; however, disease recurrence is not investigated according 
to age at diagnosis [6].
Patients aged less than 35 years at diagnosis have been consid-
ered as an important risk category [8]. Therefore, these young 
patients often require systemic chemotherapy. However, younger 
patients treated with chemotherapy alone showed an greater 
risk of relapse and death than older patients if their tumors 
expressed estrogen receptors (ER) [9,10]. Although a retrospec-
tive study suggests that chemotherapy-induced amenorrhea 
(CIA) is likely to provide clinical benefits to premenopausal 
hormone receptors-positive breast cancer patients [11], the 
endocrine effects of chemotherapy alone are insufficient for 
young patients with ER-positive tumors. The Early Breast Cancer 
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Purpose: The aims of this study were to investigate outcomes 
corresponding to age at diagnosis as categorized into 5-year 
intervals and to explore whether endocrine-responsive tumors 
display clinical benefits from endocrine therapy after chemother-
apy among young breast cancer patients. Methods: A total of 
1,171 patients who were under 40 years old at diagnosis between 
1985 and 2007 were divided into 3 subgroups: ≤30 years (Group 
I, 13.3%), 31-35 years (Group II, 30.5%), and 36-40 years (Control 
group, 56.2%). Clinicopathological factors and outcomes were 
compared using a chi-square test, the Kaplan-Meier method, 
and Cox’s hazards models. Results: There were no significant 
differences in the characteristics and treatment patterns between 
the 3 groups, except for the grade, hormone receptors expres-
sion, and use of endocrine therap. Group I showed the worst 
survival and subsequently Group II presented worse outcomes 
than the Control group, mainly among hormone receptors-posi-
tive patients. Groups I and II showed increased risks of recurrence 
and death in multivariate analyses. Among 529 hormone recep-
tors-positive patients who received chemotherapy, favorable out-
comes for patients who were treated with endocrine agents were 
demonstrated, mainly in patients aged 35 years or less. However, 
interaction tests between the use of endocrine therapy and age at 
diagnosis were not significant. Conclusion: Age at diagnosis is an 
independent prognostic factor and the age of 35 years is a rational 
cut-off among young patients. Our subgroup analysis suggests 
that endocrine therapy may provide additional benefits even in 
young breast cancers. Therefore, further researches should be 
directed towards improving outcomes for this population.
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Trialists’ Collaborative Group overview found that treatment 
with adjuvant tamoxifen for 5 years significantly reduces dis-
ease recurrence and death in ER-positive women under 50 years 
old, irrespective of chemotherapy treatment [12]. However, 
there was no subgroup analysis for the specialized case of young 
women under the ages of 35 or 40 years. Furthermore, a recent 
study demonstrated no significant additional survival benefit 
resulting from endocrine therapy in hormone receptor-positive 
patients less than 35 years old who received chemotherapy [13]; 
however, a limited number of patients younger than 35 years 
with hormone receptor-positive tumors (n=314) were analyzed 
due to many missing values.
The aims of this study were to investigate disease recurrence 
and survival according to age at diagnosis (as categorize into 
5-year intervals) among young breast cancer patients aged 40 
years or less and to explore whether young patients with en-
docrine-responsive tumors obtain additional clinical benefits 
from adjuvant endocrine therapy after administration of che-
motherapy.
METHODS
Study population
Patients were selected from the Severance Hospital Breast 
Cancer Registry Database, which contains clinicopathological 
information, treatment modalities, and details of outcomes. 
Between January 1985 and December 2007, 5,582 patients with 
breast cancer were treated at the Severance Hospital, Yonsei 
University Health System, in Seoul, Korea. The exclusion cri-
teria were as follows: pure in situ carcinoma of the breast (n=  
506), recurrent or metastatic disease (n=50), non-epithelial 
origin tumor such as phyllodes tumor, lymphoma, or sarcoma 
(n=52), incomplete data for tumor and nodal status (n=21), 
and age at diagnosis over 40 years (n=3,782). A total of 1,171 
invasive breast cancer patients, whose ages at diagnosis were 
40 years or less, were finally enrolled for analyses. The patients 
were divided into 3 groups according to their age at diagnosis: 
Group I, aged 30 years or less; Group II, aged between 31 and 
35 years; and the Control group, aged between 36 and 40 years. 
We compared clinicopathological characteristics, treatment 
patterns, and survival outcomes among the groups. 
Patients were treated with either total mastectomy or breast-
conserving surgery and sentinel lymph node biopsy or axillary 
lymph node dissection. After surgery, local radiotherapy or 
adjuvant systemic treatments were administered if the patient 
was able to tolerate it. Patients with hormone receptors-posi-
tive or -unknown (n=28) tumors received daily endocrine 
therapy with 20 mg of tamoxifen for 5 years. Forty patients 
received subcutaneously 3.6 mg of goserelin acetate every 4 
weeks for 2 years. The clinical follow-up included history tak-
ing, physical examination, laboratory tests, and radiological 
imaging tests every 6-12 months for detection of relapse. The 
classification of the tumor stage was based on the American 
Joint Committee on Cancer 6th edition criteria. The histologi-
cal grade was assessed by the modified Bloom-Richardson clas-
sification. Tumors with ≥10% nuclear-stained cells were con-
sidered to have ER and progesterone receptor (PR) positivity. 
HER2/neu immunohistochemical staining was scored from 0 
to 3+ according to the guidelines indicated for HercepTestTM 
(Dako, Glostrup, Denmark) [14]. Because the fluorescence in 
situ hybridization (FISH) test had not been performed routinely 
during most of the study period, HER2 staining was considered 
positive when strong (3+) membranous staining was observed, 
whereas cases with 0 to 2+ were regarded as negative.
Study endpoints and statistics
Locoregional recurrence was defined as tumor recurrence in 
the ipsilateral breast, chest wall, and regional lymph node. Any 
recurrence at a distant site including the contralateral axillary 
or supraclavicular lymph nodes was considered as a distant 
metastasis. Disease-free survival (DFS) was measured from the 
date of the first curative surgery to the date of the first locore-
gional or systemic recurrence or death before any type of relapse. 
Locoregional relapse-free survival (LRRFS) was calculated from 
the date of the first operation to the date of the first locoregional 
relapse or death without any type of recurrence. Distant relapse-
free survival (DRFS) was measured from the date of the first 
operation to the date of the first distant metastasis or death 
without any type of recurrence. Overall survival (OS) was cal-
culated from the date of the first surgery to the date of the last 
follow-up or death from any cause.
Comparisons between categorical variables were assessed 
using Pearson’s chi-square test or Fisher’s exact test. Survival 
curves were plotted using the Kaplan-Meier method. Inter-
group differences in the survival time were accessed by the log-
rank test. Multivariate analyses were carried out using the Cox 
proportional hazards model. All statistical tests were two-sided 
and a p-value <0.05 was considered statistically significant. 
The PASW® Statistics 18 (SPSS Inc., Chicago, USA) was used 
for all statistical analyses.
RESULTS
Among a total of 1,171 patients eligible for this study, 156 
(13.3%) were categorized into Group I, 357 (30.5%) were Group 
II, and 658 (56.2%) were a Control group of premenopausal 
breast cancer patients aged between 36 and 40 years. The mean 
age at diagnosis and the follow-up duration were 35.3 years 
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old and 72.2 months, respectively. The characteristics of each 
subgroup are demonstrated in Table 1. Most of our study pop-
ulation showed ductal type (n=1,045, 89.2%) carcinomas and 
106 (9.1%) showed special types, including papillary, mucinous, 
medullary, tubular, metaplastic, and apocrine carcinomas. There 
were no significant differences in histologic type, tumor and 
node stage among the 3 groups. Among patients who were 
available for histologic grading (n=780, 66.6%), Group I pa-
tients showed frequent poorly-differentiated tumors. Group I 
or II patients presented a higher proportion of ER- or PR-neg-
ative tumors. HER2 expression was not different among the 3 
groups.
Details of treatment patterns are presented in Table 2. Among 
our study population, 116 (9.9%) patients with locally advanced 
breast cancer received preoperative chemotherapy containing 
an anthracycline-based regimen with or without taxane. Group 
I patients more frequently received neoadjuvant chemotherapy 
based on taxane regimens, but no significant difference was 
found for regimens of neoadjuvant chemotherapy (data not 
shown). Local therapeutic modalities were also not different 
among the 3 groups. Of 1,161 patients, 982 (84.6%) received 
adjuvant chemotherapy and no significant difference in the use 
of chemotherapy was determined among the 3 groups. Endo-
crine therapy was more frequently administered in the Con-
trol group, because endocrine-responsive tumors were signifi-
cantly higher in those patients (Table 1).
Five-year DFS, LRRFS, DRFS, and OS rates of our whole 
study population were 73.5%, 78.2%, 76.4%, and 83.6%, respec-
tively. The Kaplan-Meier survival curves according to age at 
diagnosis are shown in Figure 1. Group I patients showed the 
worst survival and subsequently Group II presented worse 
outcomes than the Control group (Figure 1A for DFS, p=  
0.014; Figure 1B for LRRFS, p=0.001; Figure 1C for DRFS, 
p=0.009; and Figure 1D for OS, p<0.001, respectively). There 
was no statistically significant difference in the survival out-
comes between Group I and Group II patients, although Group 
I showed poorer survival than Group II. These significant asso-
ciations were statistically maintained in 625 hormone recep-
tors-positive patients (DFS, p=0.003; LRRFS, p<0.001; DRFS, 
p=0.004; and OS, p<0.001, respectively), but not in 293 pa-
tients of the hormone receptors-negative subgroups (DFS, p=  
0.313; LRRFS, p=0.305; DRFS, p=0.209; and OS, p=0.081, 
respectively). In multivariate analyses, being in Group I or 
Group II was revealed to be significant predictor of poorer 
disease outcomes and survival after adjustment for tumor and 
nodal status, ER, and treatment with chemotherapy and endo-
crine therapy (Table 3). Also, as we expected, the tumor stage, 
nodal status, and use of systemic chemotherapy were significant 
prognostic factors among our young breast cancer patients.
Table 1. Clinicopathological characteristics
Factors
Group I (%) 
(≤30 yr, 
n=156)
Group II (%) 
(31-35 yr, 
n=357)
Control  
group (%) 
(36-40 yr, 
n=658)
p-value
Histologic type 0.424
   Ductal 138 (88.5) 323 (90.5) 584 (88.8)
   Lobular 1 (0.6) 4 (1.1) 15 (2.3)
   Special 17 (10.9) 30 (8.4) 59 (9.0)
Tumor stage 0.661
   T0/Tis 2 (1.3) 6 (1.7) 11 (1.7)
   T1 60 (38.5) 134 (37.5) 286 (43.5)
   T2 82 (52.6) 184 (51.5) 317 (48.2)
   T3 9 (5.8) 28 (7.8) 37 (5.6)
   T4 3 (1.9) 5 (1.4) 7 (1.1)
Node stage 0.190
   N0 86 (55.1) 173 (48.5) 359 (54.6)
   N1 37 (23.7) 105 (29.4) 189 (28.7)
   N2 16 (10.3) 39 (10.9) 63 (9.6)
   N3 17 (10.9) 40 (11.2) 47 (7.1)
Grade (n=780)     0.085
   I 18 (20.7) 46 (18.8) 90 (20.1)
   II 39 (44.8) 133 (54.3) 261 (58.3)
   III 30 (34.5) 66 (26.9) 97 (21.7)
ER (n=938) 0.034
   Negative 52 (49.5) 123 (43.3) 205 (37.3)
   Positive 53 (50.5) 161 (56.7) 344 (62.7)
PR (n=918) 0.005
   Negative 52 (51.5) 130 (46.9) 203 (37.6)
   Positive 49 (48.5) 147 (53.1) 337 (62.4)
HER2 (n=658) 0.512
   Negative 61 (81.3) 135 (75.0) 304 (75.4)
   Positive 14 (18.7) 45 (25.0) 99 (24.6)
ER=estrogen receptor; PR=progesterone receptor; HER2=human epider-
mal growth factor receptor 2.
Table 2. Treatment patterns
Factors
Group I
No. (%)
Group II
No. (%)
Control 
No. (%)
p-value
Neoadjuvant chemotherapy 0.899
   Not done 142 (91.0) 322 (90.2) 591 (89.8)
   Done 14 (9.0) 35 (9.8) 67 (10.2)
Type of surgery 0.268
   Breast-conserving surgery 49 (31.4) 89 (24.6) 171 (26.0)
   Total mastectomy 107 (68.6) 269 (75.4) 487 (74.0)
Radiotherapy (n=1,123) 0.906
   Not done 83 (54.6) 193 (56.4) 347 (55.2)
   Done 69 (45.4) 149 (43.6) 282 (44.8)
Adjuvant chemotherapy  
   (n=1,161)
0.125
   Not done 28 (17.9) 43 (12.2) 108 (16.5)
   Done 128 (82.1) 309 (87.8) 545 (83.5)
Endocrine therapy (n=1,126) <0.001
   Not done 102 (67.1) 206 (60.2) 319 (50.5)
   Done 50 (32.9) 136 (39.8) 313 (49.5)
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Figure 1. (A) Disease-free, (B) locoregional relapse-free, (C) distant relapse-free, and (D) overall survival curve. The blue line represents Group I, the 
red line represents Group II, and the green line represents the Control group.
Table 3. Multivariate analyses for survival
Factors
DFS LRRFS DRFS OS
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age at diagnosis (yr)
   ≤30 1.947 1.347-
2.813
<0.001 2.009 1.337-
3.020
0.001 2.119 1.447-
3.103
<0.001 2.373 1.521-
3.703
<0.001
   31-35 1.338 1.023-
1.751
0.034 1.544 1.153-
2.068
0.004 1.257 0.940-
1.681
0.122 1.571 1.122-
2.200
 0.009
Tumor stage (T2-4) 1.652 1.254-
2.176
<0.001 1.544 1.136-
2.098
0.006 1.892 1.398-
2.561
<0.001 1.638 1.146-
2.343
 0.007
Node stage (N1-3) 2.633 1.971-
3.517
<0.001 2.746 1.981-
3.806
<0.001 2.943 2.151-
4.026
<0.001 3.328 2.254-
4.913
<0.001
ER (negative) 0.832 0.605-
1.143
0.256 0.921 0.653-
1.300
0.640 0.951 0.678-
1.336
0.773 1.078 0.730-
1.591
 0.706
Chemotherapy 
   (not done)
2.043 1.310-
3.186
0.002 2.395 1.492-
3.846
<0.001 1.654 0.973-
2.811
0.063 2.058 1.128-
3.755
 0.019
Endocrine therapy 
   (not done)
1.259 0.927-
1.710
0.140 1.487 1.060-
2.085
0.022 1.073 0.772-
1.491
0.674 1.265 0.861-
1.860
 0.231
DFS=disease-free survival; LRRFS= locoregional relapse-free survival; DRFS=distant relapse-free survival; OS=overall survival; HR=hazard ratio; CI=confidence 
interval; ER=estrogen receptor.
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To explore whether the use of endocrine therapy provides 
additional clinical benefits to hormone receptors-positive 
patients treated with systemic chemotherapy, clinicopatholog-
ical characteristics of 529 patients with ER- and/or PR-positive 
tumors who received chemotherapy were investigated accord-
ing to treatment with endocrine therapy (Table 4). In patients 
with smaller tumor sizes and ER-positive or PR-positive tumors, 
endocrine therapy was more frequently administered. Survival 
curves of endocrine-responsive breast cancer patients treated 
with chemotherapy are shown in Figure 2 according to the use 
of endocrine therapy among all subgroups (n=529; Figure 2A, 
B), patients aged 35 years or less (n=201; Figure 2C, D), and 
patients aged between 36 and 40 years (n=328; Figure 2E, F). 
The use of endocrine therapy provided additional survival ben-
efits to all of the hormone receptors-positive subgroups that 
received systemic chemotherapy. The statistical significance 
was especially maintained in patients aged 35 years or less, but 
not in those between 36 and 40 years. When tumor and node 
stage were both entered into the Cox model, however, formal 
interaction tests between the use of endocrine therapy and age 
at diagnosis (age of 35 years or less versus age between 36 and 
40 years) were not significant for DFS (hazard ratio [HR], 1.375; 
95% confidence interval [CI], 0.712-2.656; p=0.343) and OS 
(HR, 1.105; 95% CI, 0.490-2.493; p=0.810); therefore, statistical 
interpretation should be done with caution.
DISCUSSION
Through this study, we found that patients aged 30 years or 
less show the highest risk of disease recurrence and death, and 
those between 31 and 35 years also display significantly poorer 
outcomes compared to control groups after adjusting for impor-
tant clinicopathological parameters among young breast can-
cer patients. These results are consistent with a recent study 
by the KBCS [6]. According to previous retrospective studies, 
younger patients had worse prognoses than older patients [4, 
15]. Although the control groups of those studies included 
many premenopausal patients in their 40s, our unique study 
population was composed of relatively younger breast cancer 
patients. Although our study with its relatively small sample size 
did not demonstrate significant differences in disease relapse 
and survival between Group I and Group II, our study again 
supported that an age of 35 years at the time of diagnosis is a 
reasonable cut-off value for defining young age breast cancers 
[6,7]. 
Recent studies have shown that the disease recurrence rate 
is higher in young breast cancer patients [16,17]. Our earlier 
report demonstrated that patients aged less than 35 years showed 
poorer LRRFS and DRFS [18]. These results were caused not by 
associated pathological features but by different tumor biology 
based on patient age at diagnosis and being under the age of 
35 years at the time of diagnosis was an independent prognostic 
factor in breast cancer patients. Although there were some miss-
ing values, grade III, ER-negative, and PR-negative tumors, 
often showing highly proliferative features, were significantly 
associated with patients under 35 years and when all of these 
parameters were entered into multivariate models in combi-
nation with the tumor and node stage and the use of adjuvant 
therapy, being under the age of 35 years at diagnosis was an 
independent prognostic factor for disease outcomes (HR, 1.534; 
95% CI, 1.156-2.035; p=0.003 for DFS; HR, 1.723; 95% CI, 
1.261-2.354; p=0.001 for LRRFS; HR, 1.549; 95% CI, 1.147-
2.091; p=0.004 for DRFS; HR, 2.012; 95% CI, 1.406-2.878; p<  
0.001 for OS). Until now, a limited number of studies have been 
designed to determine the molecular or genetic differences that 
occur in younger breast cancer patients. A recent study using 
comparative genomic hybridization analyses suggested that 
specific chromosomal alterations might result in a poor prog-
nosis for early-onset breast cancer [19]. Further studies should 
be attentive to molecular levels to confirm the biology of early-
onset breast cancer.
Kroman and his colleagues [20] reported that age did not 
have a significant effect on the survival of women who received 
Table 4. Characteristics of hormone receptors-positive tumors treated 
with chemotherapy without or with endocrine therapy
Factors
No endocrine  
therapy (%)  
(n=112)
Endocrine  
therapy (%)  
(n=417)
p-value
Age at diagnosis (yr) 0.233
   ≤35 48 (23.9) 153 (76.1)
   36-40 64 (19.5) 264 (80.5)
Tumor size (cm) 0.001
   ≤2 31 (14.2) 188 (85.8)
   >2 81 (26.1) 229 (73.9)
Node stage 0.927
   N0 47 (21.0) 177 (79.0)
   N1-3 65 (21.3) 240 (78.7)
Histologic grade (n=443) 0.070
   I 25 (25.3) 74 (74.7)
   II/III 59 (17.2) 285 (82.8)
ER <0.001
   Negative 35 (52.2) 32 (47.8)
   Positive 77 (16.7) 385 (83.3)
PR 0.045
   Negative 10 (12.7) 69 (87.3)
   Positive 102 (22.7) 348 (77.3)
HER2 (n=367) 0.279
   Negative 24 (8.4) 262 (91.6)
   Positive 10 (12.3) 71 (87.7)
ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal 
growth factor receptor 2.
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adjuvant cytotoxic treatment, but that it was highly implicated 
among low risk patients who did not receive adjuvant chemo-
therapy. In an earlier report, Fisher et al. [21] showed that 
adjuvant chemotherapy is beneficial for patients with low risk 
factors and is most advantageous in premenopausal women. 
These researches may imply that for young breast cancer pa-
tients, even in the early stages of cancer, more aggressive treat-
ments may be necessary. However, BRCA1 and BRCA2 muta-
tions are found more frequently in young women with breast 
cancer and are often associated with bilateral tumors or triple 
negative breast cancers, which have limited therapeutic options 
and show poorer outcomes [22-24]. Intensive surveillance and 
newly tailored therapies such as poly (ADP-ribose) polymerase 
(PARP) inhibitors should be considered [25,26].
The difference in prognosis according to age at diagnosis 
might be associated with hormonal mechanisms. This finding 
is consistently demonstrated only in hormone receptors-posi-
tive tumors [6,7,13]. However, it is controversial as to whether 
the additional use of tamoxifen after the administration of 
Figure 2. (A, C, E) Disease-free and (B, D, F) overall survival of patients treated with chemotherapy according to treatment of endocrine therapy; (A, B) 
among all subgroups with hormone receptors-positive tumors; (C, D) patients aged 35 years or less; (E, F) patients aged between 36 and 40 years. 
The blue line represents patients who received both chemotherapy and endocrine therapy and the red line represents those who received only che-
motherapy without endocrine therapy. Of 201 patients aged 35 years or less, 153 (76.1%) received chemo-endocrine therapy and 48 (23.9%) received 
chemotherapy alone. Of 328 patients aged between 36 and 40 years, 264 (80.5%) received chemo-endocrine therapy and 64 (19.5%) received che-
motherapy alone.
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chemotherapy provides significant clinical benefits to younger 
patients. In 2007, Ahn et al. [13] demonstrated no significant 
survival benefit from endocrine therapy in patients younger 
than 35 years with hormone receptors-unknown or -positive 
tumors and suggested that the poor survival of very young pa-
tients with hormone receptors-positive tumors was associated 
with tamoxifen resistance. This result was different from that 
of our subgroup analysis. Although crosstalk between ER and 
HER2 signals might be related to this result, HER2 overexpres-
sion was not significantly different regardless of age at diagnosis 
(Table 1) or use of endocrine therapy (Table 4), in agreement 
with a previous report by the KBCS [13]. Many missing HER2 
results and no FISH test in the present study means that our 
subgroup analysis requires further investigation using an inde-
pendent dataset.
Although interaction tests did not reveal statistical signifi-
cance, favorable survival was demonstrated in young hormone 
receptors-positive patients, especially those aged 35 years or 
less, who received both chemotherapy and endocrine therapy. 
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It might be compounded by regimens of chemotherapy, CIA, 
adherence to endocrine therapy, or additional use of ovarian 
function suppression. Although it has not been clearly estab-
lished whether CIA is beneficial for the survival of premeno-
pausal breast cancer patients, younger women are less likely 
to experience CIA [11]. The incidence of CIA is known to be 
associated with regimen, schedule, and dosage of chemother-
apy and additional use of tamoxifen in addition to chemother-
apy, as well as patient age [11,27]. Approximately half of our 
Group I and II patients received CMF (cyclophoaphamide, 
methotrexate, fluorouracil) chemotherapy which was mainly 
administered before the early 2000s. It is also possible that 
more young women ceased 5-year tamoxifen therapy than 
older women due to menopausal symptoms, sexual dysfunc-
tion, or desire for pregnancy. Although the effects of additional 
ovarian function suppression with or without tamoxifen have 
yet to be determined in premenopausal women who received 
chemotherapy, a small number of our patients with high risk 
factors received additional ovarian suppression because of the 
absence of CIA or recovery of menstruation after chemotherapy. 
There are many issues to be investigated regarding the impacts 
of endocrine therapy on the survival of young breast cancer 
patients and we have to await the results of an ongoing ran-
domized clinical trial (NCT00912548, KBCSG005, ASTRRA).
In conclusion, patients aged 35 years or less show significantly 
worse prognosis; therefore, an age of 35 years at the time of 
diagnosis is an independent prognostic factor and a rational 
cut-off value among young breast cancer patients. These associ-
ations are mainly demonstrated in endocrine-responsive tu-
mors: however, the implications of endocrine therapy are not 
clearly established in young premenopausal patients after the 
administration of chemotherapy. Different age distributions in 
Korea to those in Western countries and poorer prognoses for 
young breast cancer patients create the need for special consid-
eration of this population for improving outcomes. Future stud-
ies based on the molecular and genetic levels and prospective 
clinical trials should be directed towards developing effective, 
tailored therapies for each patient of this population.
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